Dynavax Amends Tender Offer Statement with Regulatory Clearances and New Lawsuits
DVAX sits 68% above its 52-week low of $9.2.
Summary
Dynavax Technologies Corporation filed an amendment to its tender offer statement, confirming the expiration of the HSR Act waiting period and German merger control clearance, while also disclosing new stockholder lawsuits challenging the acquisition by Sanofi.
Key Events · M&A and Partnerships · DVAX
-
HSR Act Waiting Period Expired
The waiting period under the HSR Act expired on January 27, 2026, satisfying a key condition for the tender offer.
-
German Merger Control Clearance Received
German merger control clearance was received on January 14, 2026, another crucial regulatory approval for the acquisition.
-
New Stockholder Lawsuits Filed
Three new stockholder lawsuits (one federal, two state) and sixteen demand letters have been filed, challenging the acquisition and seeking injunctive relief or rescission.
Analysis · DVAX · Life Sciences
This amendment provides critical updates on the ongoing acquisition of Dynavax by Sanofi. The expiration of the HSR Act waiting period and the receipt of German merger control clearance are significant positive developments, fulfilling key regulatory conditions for the tender offer to proceed. However, the disclosure of three new stockholder lawsuits and sixteen demand letters introduces potential legal hurdles and risks of delay or additional disclosure requirements for the transaction. Investors should monitor the progress of these legal challenges and the tender offer's closing conditions.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DVAX was trading at $15.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.20 to $15.73. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.